The Tamil Nadu authorities has completely revoked the manufacturing license of Sresan Prescription drugs, the corporate chargeable for the contaminated cough syrup Coldrif. They’ve additionally ordered the agency to close down its operations. This transfer is a part of a broader effort to tighten oversight of drug manufacturing within the state.
In line with the official announcement, authorities have issued orders for a complete inspection of different drug manufacturing models throughout Tamil Nadu. That is to stop related incidents sooner or later.
Investigations by the state’s Drug Management Division revealed alarming findings. Coldrif contained 48.6% Diethylene Glycol (DEG), a poisonous chemical linked to the deaths of a number of kids in Madhya Pradesh. The inspections additionally revealed that Sresan Prescription drugs had failed to stick to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP). Over 300 main and significant violations have been documented.
The corporate’s proprietor, G Ranganathan, was not too long ago arrested by a particular investigation group from Madhya Pradesh. As well as, the Enforcement Directorate (ED) carried out raids on the corporate’s premises. This included the residences of sure officers in reference to a Prevention of Cash Laundering Act (PMLA) case.
This decisive motion underscores the federal government’s dedication to strict regulation within the pharmaceutical sector. It focuses on defending public well being following one of many deadliest incidents of drug contamination in recent times.
Unicorn Indicators leverages superior AI expertise to give you highly effective market predictions and actionable inventory scans. Obtain the app at present and 10x your buying and selling & investing journey!
